Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis

References

• Ludwig RJ, Vanhoorelbeke K, Leypoldt F, et al. Mechanisms of autoantibody-induced pathology. Front Immunol. 2017;8:603.
   PubMed Web of Science ®Google Scholar
• Kridin K, Schmidt E. Epidemiology of pemphigus. JID Innov. 2021;1(1):100004.
   PubMedGoogle Scholar
• Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394(10201):882–894.
   PubMed Web of Science ®Google Scholar
• Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med. 2006;355(17):1800–1810.
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023–1036.
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.
   PubMed Web of Science ®Google Scholar
• Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. 2014;52:139–145.
   PubMed Web of Science ®Google Scholar
• Costamagna G, Abati E, Bresolin N, et al. Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic. J Neurol. 2021;268(5):1580–1591.
   PubMed Web of Science ®Google Scholar
• Muppidi S, Guptill JT, Jacob S, et al. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurol. 2020;19(12):970–971.
   PubMed Web of Science ®Google Scholar
• Jakubíková M, Týblová M, Tesař A, et al. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol. 2021;28(10):3418–3425.
   PubMed Web of Science ®Google Scholar
• Drenovska K, Vassileva S, Tanev I, Joly K. Impact of COVID-19 on autoimmune blistering diseases. Clin Dermatol. 2021;39(3):359–368.
   PubMed Web of Science ®Google Scholar
• Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372–4386.
   PubMed Web of Science ®Google Scholar
• Grevys A, Nilsen J, Sand KMK, et al. A human endothelial cell-based recycling assay for screening of FcRn targeted molecules. Nat Commun. 2018;9(1):621.
   PubMedGoogle Scholar
• Howard JF, Bril V, Burns TM, Jr., Efgartigimod MG Study Group, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661–e2673.,
   PubMed Web of Science ®Google Scholar
• Goebeler M, Bata-Csörgő Z, De Simone C, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase 2 multicentre, open-label feasibility trial. Br J Dermatol. 2022;186(3):429–439.
   PubMed Web of Science ®Google Scholar
• Howard JF, Bril V, Vu T, Jr., et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526–536.
   PubMed Web of Science ®Google Scholar
• Nixon AE, Chen J, Sexton DJ, et al. Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates. Front Immunol. 2015;6:176.
   PubMed Web of Science ®Google Scholar
• Galazaka AM. The immunological basis for immunization series, module 3: tetanus. In Global programme for vaccines and immunization, expanded programme on immunization; 1993. Geneva, Switzerland: World Health Organization.
   Google Scholar
• Chris Maple PA, Gunn A, Sellwood J, et al. Comparison of fifteen commercial assays for detecting varicella zoster virus IgG with reference to a time resolved fluorescence immunoassay (TRFIA) and the performance of two commercial assays for screening sera from immunocompromised individuals. J Virol Methods. 2009;155(2):143–149.
   PubMed Web of Science ®Google Scholar
• Maple PAC, Rathod P, Smit E, et al. Comparison of the performance of the LIAISON VZV-IgG and VIDAS automated enzyme linked fluorescent immunoassays with reference to a VZV-IgG time-resolved fluorescence immunoassay and implications of choice of cut-off for LIAISON assay. J Clin Virol. 2009;44(1):9–14.
   PubMed Web of Science ®Google Scholar
• Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the basic and clinical immunology interest section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2012;130(3 Suppl):S1–S24.
   PubMed Web of Science ®Google Scholar
• Kamchaisatian W, Wanwatsuntikul W, Sleasman J, et al. Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children. J Allergy Clin Immunol. 2006;118(6):1336–1341.
   PubMed Web of Science ®Google Scholar
• Jódar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine. 2003;21(23):3265–3272.[12804857
   PubMed Web of Science ®Google Scholar
• World Health Organization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines: replacement of WHO technical report series No. 927, Annex 2, 2013. [cited 2021 6 October]; Available from: https://www.who.int/biologicals/vaccines/TRS_977_Annex_3.pdf.
   Google Scholar
• World Health Organization. WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser, 2005;927:1–154.
   Google Scholar
• Boekel L, Steenhuis M, Hooijberg F, et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in The Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol. 2021;3(11):E778–E788.
   Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211.
   PubMed Web of Science ®Google Scholar
• Strijbos E, Tannemaat MR, Alleman I, et al. A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis. Vaccine. 2019;37(7):919–925.
   PubMed Web of Science ®Google Scholar
• Zhao X, Fang VJ, Ohmit SE, et al. Quantifying protection against influenza virus infection measured by hemagglutination-inhibition assays in vaccine trials. Epidemiology. 2016;27(1):143–151.
   PubMed Web of Science ®Google Scholar
• WHO. Recommended composition of influenza virus vaccines for use in the 2019-2020 Northern hemisphere influenza season. 2019. World Health Organization. [cited 2021 May 20].
   Google Scholar
• Maho-Vaillant M, Sips M, Golinski M-L, et al. FcRn antagonism leads to a decrease of desmoglein-specific B cells: Secondary analysis of a phase 2 study of efgartigimod in pemphigus vulgaris and pemphigus foliaceus. Front Immunol. 2022;13:863095.
   PubMed Web of Science ®Google Scholar
• Newland AC, Sánchez-González B, Rejtő L, et al. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol. 2020;95(2):178–187.
   PubMed Web of Science ®Google Scholar
• Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375(26):2570–2581.
   PubMed Web of Science ®Google Scholar
• Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol. 2017;188(3):333–341.
   PubMed Web of Science ®Google Scholar
• Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency: Causes, diagnosis, and management. Front Immunol. 2019;10:33.
   PubMed Web of Science ®Google Scholar
• Ungaro RC, Agrawal M, Park S, et al. Autoimmune and chronic inflammatory disease patients with COVID-19. ACR Open Rheumatol. 2021;3(2):111–115.
   PubMedGoogle Scholar
• Stabler S, Giovannelli J, Launay D, et al. Serious infectious events and immunoglobulin replacement therapy in patients with autoimmune disease receiving rituximab: a retrospective cohort study. Clin Infect Dis. 2021;72(5):727–737.
   PubMed Web of Science ®Google Scholar
• Kovvuru S, Nalleballe K, Onteddu SR, et al. Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic. J Neurol Sci. 2021;420:117230.
   PubMed Web of Science ®Google Scholar
• Guptill JT, Juel VC, Massey JM, et al. Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. Autoimmunity. 2016;49(7):472–479.
   PubMed Web of Science ®Google Scholar
• Schmaldienst S, Müllner M, Goldammer A, et al. Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? Rheumatology (Oxford). 2001;40(5):513–521.
   PubMed Web of Science ®Google Scholar
• Stummvoll GH, Aringer M, Jansen M, et al. Immunoadsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy. Wien Klin Wochenschr. 2004;116(21–22):716–724.
   PubMed Web of Science ®Google Scholar
• Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. Jama. 2021;325(21):2204–2206.
   PubMed Web of Science ®Google Scholar
• Deepak P, Kim W, Paley MA, et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv. 2021;2021.04.05.21254656.
   PubMedGoogle Scholar
• Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80(10):1330–1338.
   PubMed Web of Science ®Google Scholar
• Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021;80(10):1306–1311.
   PubMed Web of Science ®Google Scholar
• Haberman RH, Herati R, Simon D, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 2021;80(10):1339–1344.
   PubMed Web of Science ®Google Scholar
• Picchianti-Diamanti A, Aiello A, Laganà B, et al. Immunosuppressive therapies differently modulate humoral- and T-cell-specific responses to COVID-19 mRNA vaccine in rheumatoid arthritis patients. Front Immunol. 2021;12:740249.
   PubMed Web of Science ®Google Scholar
• Spiera R, Jinich S, Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis. 2021;80(10):1357–1359.
   PubMed Web of Science ®Google Scholar
• Avouac J, Miceli-Richard C, Combier A, et al. Risk factors of impaired humoral response to COVID-19 vaccination in rituximab treated patients. Rheumatology (Oxford). 2022;61(SI2):SI163–SI168.
   PubMed Web of Science ®Google Scholar
• Bugatti S, De Stefano L, Balduzzi S, et al. Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis. Ann Rheum Dis. 2021;80(12):1635–1638.
   PubMed Web of Science ®Google Scholar
• Wong SY, Dixon R, Martinez Pazos V, et al. Serologic response to messenger RNA coronavirus disease 2019 vaccines in inflammatory bowel disease patients receiving biologic therapies. Gastroenterology. 2021;161(2):715–718.e4.
   Web of Science ®Google Scholar
• Madelon N, Lauper K, Breville G, et al. Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis. 2021:ciab954.
   Web of Science ®Google Scholar
• Waldmann TA, Terry WD. Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin. J Clin Invest. 1990;86(6):2093–2098.
   PubMed Web of Science ®Google Scholar
• Ardeniz Ö, Unger S, Onay H, et al. β2-Microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system. J Allergy Clin Immunol. 2015;136(2):392–401.
   PubMed Web of Science ®Google Scholar
• Castrucci MR. Factors affecting immune responses to the influenza vaccine. Hum Vaccin Immunother. 2018;14(3):637–646.
   PubMed Web of Science ®Google Scholar
• Pellini R, Venuti A, Pimpinelli F, et al. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMed. 2021;36:100928.
   PubMedGoogle Scholar